On Wednesday, August 8, a federal appeals court rejected an antitrust challenge by 23 beer drinkers to Anheuser-Busch InBev’s US$107 billion purchase in 2016 of SABMiller, which they claimed would thwart competition and raise prices in the US beer market.
The 9th Circuit Court of Appeals in Portland, Oregon stated that SABMiller’s agreement with antitrust regulators to divest its US beer business, by selling its stake in the MillerCoors joint venture to Molson Coors Brewing, would prevent increased concentration in the industry.
It also rejected as speculative the argument that the merger violated the Clayton Act because it gave Molson Coors an incentive to adopt Anheuser’s distribution practices, to combat its rival’s newly increased size.
That law requires consumers to properly allege that a merger “creates an appreciable danger or a reasonable probability of anticompetitive effects in the relevant market,” Circuit Judge Margaret McKeown wrote for a three-judge panel. “[The] consumers’ allegations do not belly up to this bar.”
Anheuser-Busch InBev’s brands include Budweiser and Bud Light, Beck’s, Corona, Hoegaarden, Stella Artois, the craft beers Goose Island and Blue Point, and many others.
Full Content: Yahoo News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan